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ditures for health insurance funds have been remained under
control.
PCV47
ROSUVASTATIN 40MG VERSUS ATORVASTATIN 80MG IN
HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLAEMIA:
ECONOMIC ANALYSIS OF THE POLARIS STUDY
Miller PS1, Leiter LA2, Davies A3, Sosef F4
1AstraZeneca UK, Macclesﬁeld, Cheshire, UK; 2University of Toronto,
Toronto, Ontario, Canada; 3MEDTAP International, London, UK;
4Astrazeneca UK, Macclesﬁeld, Cheshire, UK
OBJECTIVES: POLARIS is a 26-week, double-blind, ran-
domised study comparing the efﬁcacy of rosuvastatin (RSV) 
40mg with atorvastatin (ATV) 80mg in high-risk patients
(known CHD or CHD-risk equivalent, as deﬁned by NCEP ATP
III) with hypercholesterolaemia. Using a secondary prevention
model, results from POLARIS were used to estimate longer-term
costs and beneﬁts. METHODS: Efﬁcacy data from POLARIS
(TC, HDL-C, and TG) were used as input to the model. Markov
models were run in 4-year cycles over 20 years, from age 55 to
76 years for men and women separately. Secondary CHD risk
was based on Framingham data (d’Agostino et al. AHJ 2000)
but calibrated to British Regional Heart Study (Brindle et al. BMJ
2003). Estimates for life expectancy, health-care costs and
quality-adjusted life years (QALYs) were assigned to patients as
they transitioned through the model. RESULTS: RSV 40mg
improved levels of TC and HDL-C more than ATV 80mg (-41%
vs. -39%; +11.0 vs. +6.2%, respectively).The model predicts
that more secondary CHD events and deaths are avoided 
with RSV 40mg compared with ATV 80mg in both high-risk
men and women; hence, more life-years and QALYs are gener-
ated and event costs are lower. More patients survive on treat-
ment and therefore total costs with RSV 40mg are slightly
higher. Cost per life year gained (men: £1113, women: £1065)
and QALY gained (men: £2091, women: £3079) are favourable
for RSV 40mg. CONCLUSIONS: RSV 40mg is likely to be more
effective both clinically and economically than ATV 80mg for
the secondary prevention of CHD.
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ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL
ATTAINMENT BY SWITCHING PATIENTS TO DUAL
INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN
Davies G1, Nocea G2,Alemao E3,Yin D3, Cook J1
1Merck and Co, Blue Bell, PA, USA; 2Merck, Sharp & Dohme, Madrid,
Spain; 3Merck and Co, Whitehouse Station, NJ, USA
While treatment guidelines recommend lowering cholesterol to
target levels, many remain above goal (LDL-C >100mg/dL for
CHD/diabetic patients and LDL-C >130mg/dl for other non-
CHD high risk individuals). OBJECTIVE: To assess the change
in LDL-C and goal attainment rates due to switching patients to
an Ezetimibe/Simvastatin dose titration strategy, compared with
a simulated statin monotherapy dose titration strategy.
METHOD: A decision-analytic model was developed to project
goal attainment at end of 1-year after therapy change. Clinical
trial data were used to estimate LDL-C reductions for different
treatment strategies. The model was run for a population of 504
Spanish patients (237 CHD/diabetic and 267 non-CHD high risk
patients) that had not reached LDL-C goal levels 3-months after
starting statin therapy. Patients not at goal where up titrated (till
goal attainment or to the maximum dose whichever was ﬁrst)
every 3 months both in the Ezetimibe/Simvastatin (only simvas-
tatin titrated) and in the statin monotherapy titration arms.
RESULTS: Mean age was 60.8 (SD 9.8) years, 47.8% female,
lipid proﬁle (mg/dl) at three months on statin monotherapy was
LDL-C 182.3 (SD 35.1), TC 262.1 (SD 39.5), HDL-C 50.8 (SD
14.1), triglycerides 150.1 (SD 82.5). Ezetimibe/Simvastatin
therapy is projected to achieve a 82.6% goal attainment rate,
compared with 46.0% projected for the statin titration strategy.
With respect to LDL-C reductions, Ezetimibe/Simvastatin would
achieve a 38.2% reduction over baseline, compared with a
24.5% with the statin titration strategy. In the statin arm, 73.9%
of the patients reached the statin maximum dose, whereas in the
Ezetimibe/Simvastatin arm, only 23.5% of the patients did so.
CONCLUSION: Compared to statin monotherapy titration,
switching patients not at goal on statin monotherapy to Ezetim-
ibe/Simvastatin followed by titration is projected to get 36.6%
additional patients to goal and reduce LDL-c by 13.7%.
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BELGIAN EVALUATION OF SCREENING AND TREATMENT OF
HIGH RISK PATIENTS BASED ON WAIST AND AGE (BEST)
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OBJECTIVE: The objective of this study was to describe the
burden of modiﬁable risk factors and of the total CV risk in a
population, free of CVD, selected in general practice, on the basis
of age (40–75yrs) and waist circumference (>=94cm in men and
>=80cm in women). METHODS: In total, 619 Belgian GPs
recruited consecutive patients during spring 2004. A central lab
analysed fasting blood samples. RESULTS: Complete data on
8587 patients were obtained. Mean age was 58yrs (47%
women). Mean BMI and waist were 30.1kg/m2 and 99cm for
women and 30.1kg/m2 and 107cm for men. Eighteen-percent
had diabetes (D) either known and treated (14%) or newly
detected, based on fasting glucose levels (4%). Of the non-
diabetic subjects (ND), 25% had ° 3 metabolic syndrome risk
factors (NCEP-ATP III criteria). Twenty-four percent of the total
population was smoking and 84% did not engage in regular
physical activity. Seventy-seven percent of ND had LDL 
cholesterol >=115mg/dl & 78% of D had LDL cholesterol
>=100mg/dl. Only 31% of subjects on lipid lowering drugs had
TC < 190 and LDL <115mg/dl. 49% of ND had BP >=140/90
mmHg and 91% of the D had BP >=130/80mmHg. Total CV
risk in the ND was estimated using the SCORE chart calibrated
for Belgium. Total risk >=5% for dying from CVD in the coming
10yrs was present in more than 40% of men and in more than
20% of women. CONCLUSION: Waist measurement is an easy
and inexpensive tool to detect, in the middle-aged population
free of CVD, a subgroup with a large variety of modiﬁable risk
factors and at high risk for CV death. A large majority of them
is physically inactive, an unacceptable proportion is smoking and
both total cholesterol and blood pressure are insufﬁciently
managed.
PCV50
A MULTILEVEL ANALYSIS ON PRESCRIBED STATINES IN A
BOLOGNA HEALTH AUTHORITY FROM 2000 TO 2003
Roli G1, Cavrini G1, Pandolﬁ P2
1University of Bologna, Bologna, Italy, Italy; 2Health Authority of
Bologna, Bologna, Italy, Italy
OBJECTIVES: The main aim is to evaluate the variability of
practitioners’ prescribing behaviour on statines in AUSL Bologna
South from 2000 to 2003, as well as to quantify how much such
a behaviour depends on culture, education and policy of practi-
tioner. METHODS: A multilevel model has been built to reﬂect
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the hierarchical data structure: patients with prescribed statines,
nested in their prescribing general practitioner. The multilevel
model advantage lies on the fact that one can insert, in the same
analysis, independent variables related either to the general prac-
titioners (level-2) or to the patients (level-1). Furthermore, one
can quantify the variability at each level, which is, prescribing
practitioners’ variability and patients’ variability. Particularly, a
random intercept model has been built, where the response vari-
able is the sum of the daily dosages given in the prescriptions 
for each patient. Actually, we refer to generalized linear model
theory, because the dependent variable is Gamma-distributed.
RESULTS: The regressors referred to the patients (level-1) and
inserted into the model are: age, sex, and use of other cardio-
vascular drugs. The level-2 independent variables, hence referred
to practitioner, are: age, sex, specialization (yes/no) on cardiol-
ogy, ratio of statines’ prescriptions on total number of prescrip-
tions of cardiovascular drugs and percentage of patients over 65
years old. The largest part of variability is obviously due to
patients’ effect. Regarding the regressions of level 2, the age of
the practitioner provides a negative and signiﬁcant coefﬁcient,
indicating a tendency towards “prescriptive thrift” by older
doctors. CONCLUSIONS: It appears to be a clear evidence that
the consumption of statines and, generally, of drugs cannot be
simply reduced to individual characteristics. From a method-
ological point of view, it has been shown that multilevel
approach provides a coherent framework, in spite of the lack of
applications to health sciences.
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PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY
SWITCHING PATIENTS TO DUAL INHIBITION THERAPY
(EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN
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While treatment guidelines recommend lowering cholesterol to
target levels, many remain above goal (LDL-C >100mg/dL for
CHD and diabetic patients and LDL-C >130mg/dl for other 
non-CHD high risk individuals). OBJECTIVE: To project the
change in LDL-C and goal attainment rates by treating patients
with Ezetimibe/Simvastatin 10/20mg, and compare it with what
was observed in clinical practice with statin monotherapy.
METHOD: A decision-analytic model was developed to project
goal attainment at end of one year after therapy change. Short
term clinical trial data were used to estimate LDL-C reductions
for Ezetimibe/Simvastatin therapy. The model was run for a pop-
ulation of 504 Spanish patients (237 CHD/diabetic and 267 non-
CHD high risk patients) that had not reached LDL-C goal levels
3 months after starting statin therapy. Patients were assumed to
remain treated with Ezetimibe/Simvastatin 10/20mg for 12
months from then, and their results compared with those
observed in real life in the same time period. RESULTS: Mean
age of study population was 60.8 (SD 9.8) years, 47.8% female,
lipid proﬁle (mg/dl) at three months on statin monotherapy was
LDL-C 182.3 (SD 35.1), TC 262.1 (SD 39.5), HDL-C 50.8 (SD
14.1), triglycerides 150.1 (SD 82.5). Ezetimibe/Simvastatin
10/20mg. therapy is projected to achieve a 53.4% goal attain-
ment rate, were as a 2.0% goal attainment rate was observed in
clinical practice (were 8% of patients were up titrated on statin
dose during ﬁrst year). With respect to LDL-C reductions, Eze-
timibe/Simvastatin 10/20mg. could achieve a 31.5% reduction
over baseline, vs. a 4.9% achieved in real life clinical practice
during similar time period. CONCLUSION: Treating patients
not at goal on statin monotherapy with Dual-inhibition therapy
(Ezetimibe/Simvastatin 10/20mg) is projected to greatly improve
the results of lipid-lowering therapy compared to statin
monotherapy observed in real life clinical practice.
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IMPACT OF COMPLIANCE AND PERSISTENCE OF
TREATMENT WITH VALSARTAN ON HYPERTENSION
CLINICAL OUTCOMES
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4Geisinger Health System, Danville, PA, USA
OBJECTIVES: The relationship between compliance and persis-
tence with hypertension therapies and clinical outcomes has 
not previously been quantiﬁed. In addition, little information is
available regarding the “real-world” effectiveness of hyperten-
sion therapies. In this study, we evaluated the impact of compli-
ance and persistence with valsartan (Diovan®) therapy on blood
pressure outcomes using ofﬁce-based effectiveness data.
METHODS: We analyzed data from the Geisinger Clinic, a U.S.
regional health care network with 52 primary care and specialty
clinics. Information on patient characteristics and longitudinal
data on prescribed medications and use and ofﬁce blood pres-
sure reading were obtained from the network’s electronic health
record database. Hypertension status was based on JNC VII
guidelines. RESULTS: Increased compliance with use of valsar-
tan therapy (i.e., taking therapy as prescribed) was associated
with a signiﬁcant decrease in systolic and diastolic blood pres-
sure 6 and 12 months after the initial prescription. At 12 months,
a 10% increase in compliance resulted in decreases in systolic
and diastolic blood pressure of 1.3 and 0.5mmHg (respectively)
and a 17% increase in having controlled blood pressure. Greater
persistence with valsartan therapy (i.e., time on therapy follow-
ing control of blood pressure) was also associated with signiﬁ-
cant decreases in blood pressure. For each additional month of
treatment persistence following blood pressure control, systolic
and diastolic blood pressure at one year decreased by 1.4 and
0.5mmHg, respectively. CONCLUSIONS: We have demon-
strated that both compliance and persistence with valsartan
therapy are associated with signiﬁcant improvements in blood
pressure control. Further, having access to ofﬁce-based blood
pressure data, we were able to evaluate treatment effectiveness
rather than only efﬁcacy. Improved compliance and persistence
with hypertension therapy is likely to result in long-term
improvement in patient outcomes, such as decreased cardiovas-
cular complications.
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PATIENT PROFILE AND STATINS EFFECTIVENESS IN 
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Atorvastatin produces the highest cLDL reduction among the
statins commercialized in Spain, as demonstrated in clinical
trials. OBJECTIVE: To retrospectively compare the effectiveness
of different statins in terms of CVRF control, in daily clinical
practice. METHODS: A total of 9001 subjects from four
primary care centres in Catalonia were retrospectively examined.
A total of 9001 hypertensive and/or dyslipidemic patients from
Managed Care programmes were selected. The following vari-
ables were retrospectively compared for the different statins: 1)
the level of cardiovascular risk as deﬁned by ATP III criteria; 2)
average number of CVRF; and 3) average proportion of subjects
with appropriately controlled CVRF according to ATP III crite-
ria. RESULTS: 1) The average proportion of patients with pre-
